ATC kod: N04BC09
Det saknas studier som analyserat könsskillnader i effekt av rotigotin.
Vissa studier rapporterar en ökad risk för impulskontrollstörning hos män jämfört med kvinnor vid behandling med parkinsonläkemedel, medan andra studier inte visar några könsskillnader.
The reported incidence and prevalence of Parkinson’s disease (PD) is slightly higher in men than in women. It seems that men develop PD earlier in life compared to women. Several possible explanations behind these sex differences have been suggested; the protective role of estrogens in premenopausal women, and different profiles of risk factors (environmental and/or genetic). Sex differences in clinical presentations of PD have also been reported. Since the activities of daily living might differ between men and women with PD, different treatment strategies can be recommended to men and women with PD .
Women and men have shown to have similar plasma concentrations of rotigotine (body weight normalized) . Rotigotine treatment is initiated at a low dose and is gradually titrated according to clinical tolerability to obtain the optimum therapeutic effect. It is not necessary to adjust the dose based on patient’s sex, weight or age .
No studies with a clinically relevant sex analysis regarding the effects of rotigotine have been found.
The increased risk of impulse control disorder with use of dopamine agonists is well known [2-6]. One observational study on dopamine agonists (n=642, approx. 2/3 men) reports a higher frequency of impulse control disorder in men compared to women in patients using dopamine agonists .A small study on transdermal rotigotine (11 men, 17 women) showed a higher risk in men . However, in a transversal study of patients on a single nonergolinic dopamine agonist (pramipexole, ropinirole, or rotigotine) (145 men, 88 women) no difference in risk between men and women was reported .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Något fler män än kvinnor hämtade ut depotplåster innehållande rotigotin (ATC-kod N04BC09) på recept i Sverige år 2019, totalt 929 män och 919 kvinnor .
Faktagranskat av: Mia von Euler, Diana Rydberg
Godkänt av: Karin Schenck-Gustafsson